Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04478643
Other study ID # PERIOPRO np.: 3965
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 7, 2020
Est. completion date June 2024

Study information

Verified date February 2024
Source Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Contact Magda Mensi
Phone +390303995784
Email magda.mensi@unibs.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Literature shows the potential effectiveness of L. reuteri as an adjunct to non-surgical periodontal therapy in initial treatment of periodontitis, but also underlines the limits of the conclusions, and the heterogeneity and limited sample size of the available studies. Therefore, there is a need for longer-term, randomized, controlled studies. Moreover, only one study addresses the use of this probiotic during the supportive therapy, in particular in patients with severe forms of periodontitis, and only few patients were included. Patients meeting the criteria of periodontitis stage III and IV, grade C are considered to be affected by severe and advanced forms of periodontitis with a rapid rate of progression. This group of patients could particularly benefit from supplements for the maintenance of periodontal health. The hypothesis of the present randomized controlled trial is that the adjunctive use of probiotic treatment can bring clinical and microbiological advantages during the supportive therapy of periodontal disease, and reduce the number of residual pockets. To test this hypothesis, the patients, upon initial evaluation, will be divided in 2 study groups and, after a session of professional oral hygiene, will be prescribed one of the therapies below: - PLACEBO: The patients of the control group will receive control lozenges without live bacteria; - TEST: The patients of the probiotic group will receive probiotic lozenges containing Lactobacillus reuteri DSM 17938 and Lactobacillus reuteri ATCC PTA 5289 (a minimum of 2 × 108 colony-forming units L. reuteri Prodentis/lozenge, BioGaia AB). The probiotic and control lozenges will be identical in taste, texture and appearance. The lozenges will be given to all patients to consume at home. The patients will be instructed to dissolve them on their tongue twice a day, preferably after brushing, for 3 weeks. Periodontal and microbiological parameters will be evaluated at 3 and 6 months after the initial therapy, and compared between the two groups.


Description:

Probiotics are defined as 'live microorganisms which, when administered in adequate amounts, confer a health benefit on the host'. The influence of probiotics on pathogens flora can derive from three principal modes of action: innate and acquired host defense modulation, production of antibacterial substances and competitive exclusion mechanism. In particular, Lactobacillus reuteri has been studied for its antibacterial and anti-inflammatory properties. It is a heterofermentative bacterium and the distinct strains have different characteristics. In particular it acts as an antibiotic, induces oxidative stress on pathogens, is resistant to proteolytic and lipolytic and present anti-inflammatory properties. TRIAL DESIGN Parallel-arm, mono-center, statistician operator and examiner blinded RCT. The trial will have 6 months of duration. STUDY POPULATION Forty-four (44) adults, aged 18-75 years, meeting the criteria of periodontitis stage III and IV, grade C, will be entered into study. It is expected that forty (40) subjects will complete the study. PRIMARY OUTCOMES - Change in (Pocket Probing Depth) PPD: change in mean value for each patient will be calculated. Baseline values will be compared to the values recorded at follow-up visits. SECONDARY OUTCOMES - Pocket closure - Risk of progression of periodontitis - Change in BoP: change in percentage of sites positive to bleeding on probing. - Change in Plaque Index (PI): change in percentage of sites with presence of plaque. Baseline values will be compared to the values recorded at follow-up visits. - Change in Periodontal Attachment Level (PAL): change in mean value for each patient will be calculated. Baseline values will be compared to the values recorded at follow-up visits. - Change in Recession (REC): change in mean value for each patient will be calculated. Baseline values will be compared to the values recorded at follow-up visits. - Changes in microbial composition and proportion of sequences identified as Lactobacillus reuteri in the deepest residual pockets


Recruitment information / eligibility

Status Recruiting
Enrollment 44
Est. completion date June 2024
Est. primary completion date February 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Signed Informed Consent Form. - Male and female subjects, aged 18-75 years, inclusive. - Good general health (free of systemic diseases such as diabetes, HIV infection or genetic disorder, ongoing malignant disease of any type that could influence the outcome of the treatment and might interfere with the evaluation of the study objectives). - History of periodontitis staging III or IV grading B or C - At least 2 sites with probing depth =6 mm or pockets of 5 mm with bleeding on probing in two different quadrants. - Previous periodontal non-surgical treatment at least 3 months maximum 6 months. - Availability for the 6-month duration of the study for an assigned subject. Exclusion Criteria: - Not willing to follow the agreed protocol. - Presence of orthodontic appliances. - Smokers (more than 10 cigarettes per day) - Chronic obstructive pulmonary disease and asthma. - Tumors or significant pathology of the soft or hard tissues of the oral cavity. - Current radiotherapy or chemotherapy. - Pregnant or lactating women. - Current or past (within 3 months prior to enrolment) administration of medications that may influence periodontal conditions and/or interfere with healing following periodontal treatment (i.e., corticosteroids, calcium channel blockers, systemic antibiotics, ...). - History of allergy to Erythritol or chlorexidine. - Restorations on the teeth to be treated which may interfere with treatment administration and/or scoring procedures, at the discretion of the examiner. - Use of systemically administered antibacterial agents or probiotics 3 months prior to enrollment.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Probiotic: Lactobacillus Reuteri
Lactobacillus reuteri ATCC PTA 5289 (a minimum of 2 × 108 colony-forming units L. reuteri Prodentis/lozenge, BioGaia AB)
Placebo
Placebo lozenge. Will be identical in taste, texture and appearance to the Probiotic one.

Locations

Country Name City State
Italy Magda Mensi Brescia Lombardia

Sponsors (1)

Lead Sponsor Collaborator
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in PD (periodontal depth) Change in mean PD value for each patient measured (from the gingival margin to the bottom of the pocket). Baseline values will be compared to the values recorded in the follow-up visits. baseline, 3 and 6 months
Secondary Risk progression of the periodontitis and the need of periodontal surgery Change in percentage of patient who need periodontal surgery. Periodontal stability is defined as < 10% of sites bleeding on probing, no probing depths of 4 mm or greater that bleed on probing, and lack of progressive periodontal destruction. Baseline values will be compared to the values recorded in the follow-up visits. 6 months
Secondary Pocket closure Change in percentage of site > 4mm. Baseline values will be compared to the values recorded in the follow-up visits. baseline, 3 and 6 months
Secondary Microbiological changes changes in microbial composition (kind of bacteria) and proportion (% of pathogen) of sequences identified as Lactobacillus reuteri in the deepest residual pockets baseline, 3 and 6 months
Secondary change in REC (Clinical Gingival Recession) Change in mean of REC value for each patient should be calculated. Baseline values will be compared to the values recorded in the follow-up visits. baseline, 3 and 6 months
Secondary change in CAL (Clinical Attachment Level) Change in mean of CAL value for each patient should be calculated. Baseline values will be compared to the values recorded in the follow-up visits. baseline, 3 and 6 months
Secondary Change in BOP (Bleeding on Probing) Change in percentage of sites positive to bleeding on probing. Baseline values will be compared to the values recorded in the follow-up visits. baseline, 3 and 6 months
Secondary Change in PI (Plaque Index) Change in percentage of site with plaque. Baseline values will be compared to the values recorded in the follow-up visits. baseline, 3 and 6 months
See also
  Status Clinical Trial Phase
Completed NCT04712630 - Non-Incised Papillae Surgical Approach (NIPSA) With and Without Graft N/A
Recruiting NCT03997552 - NIPSA Versus Marginal Approach by Palatal Incision and MIST in Periodontal Regeneration N/A
Completed NCT04478864 - Knowledge, Practice and State of Periodontal Health
Completed NCT03507868 - YKL-40 and IL-6 Levels in Periodontal Disease
Completed NCT05720481 - Impact of Periodontal Treatment on Growth Differentiation Factor-15 Levels N/A
Recruiting NCT06052150 - Oral Health In Cirrhosis of the Liver (ORACLE)
Recruiting NCT06025955 - Evaluation of Outcomes of Minimally Invasive Non- Surgical Versus Surgical Therapy in Furcation Involvement. N/A
Recruiting NCT03510702 - SCREENING OF EPIGENETIC BIOMARKERS (miRNAs) IN THE GINGIVAL SULCUS
Completed NCT05631600 - Manuka Honey as an Adjunct to Non-surgical Periodontal Therapy: Clinical Study Phase 2/Phase 3
Active, not recruiting NCT05068778 - Development of an AI App to Improve Compliance in Periodontal Maintenance Patients
Not yet recruiting NCT05178563 - Mechanisms of Acute Inflammation Following Periodontal Treatment N/A
Recruiting NCT06086821 - Clinical Relevance of Different Time of Periodontal Re-evaluation N/A
Recruiting NCT06224699 - Toothpaste With Sodium Carbonate in Patients With Gingivitis N/A
Not yet recruiting NCT05721313 - Vital Root Amputation in Molars With Advanced Periodontal Furcation Involvement: a Preliminary Study N/A
Completed NCT06306937 - Serum Levels of Vitamin D and IL8 in Patients With Periodontitis
Completed NCT06040944 - Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients
Recruiting NCT04669717 - Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies Phase 4
Completed NCT05576142 - Oral Findings in Pediatric Patients With Allergic Rhinitis and/or Asthma
Completed NCT03694496 - The Effectiveness of an Oral Health Education Programme of Adolescents in Hong Kong N/A
Completed NCT04017078 - Assessment of Carotid Artery Calcifications